TRVI

Trevi Therapeutics, Inc. (TRVI) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2025. Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company has no approved products and has not generated any revenue from product sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by $562,000 (5.2%) compared to Q1 2024, primarily driven by a $993,000 decrease in R&D expenses.
• R&D Expenses: Decreased due to lower clinical development costs for the Human Abuse Potential (HAP) study, which was actively enrolling in the prior year. This was partially offset by increased personnel and stock-based compensation expenses.
• G&A Expenses: Increased by $557,000 (18.0%) due to higher stock-based compensation and personnel costs.
• Interest Income: Increased by $127,000 to $1.1 million, reflecting higher average balances of cash and marketable securities.
• Financing Activity: Generated $8.7 million in net cash from financing activities, primarily from $8.2 million in proceeds from warrant exercises and $0.7 million from stock option exercises.

Outlook, Guidance, and Risks

Clinical Progress:

• Phase 2b CORAL (IPF): Enrollment completed in February 2025; topline results expected in Q2 2025. A Phase 3 program is planned for initiation in H1 2026, subject to positive results.
• Phase 2a RIVER (RCC): Announced positive topline data in March 2025, meeting the primary endpoint with a statistically significant reduction in cough frequency. The company is designing the next trial for RCC.
• Phase 1 TIDAL (IPF): Screening initiated to evaluate respiratory function and safety.

• As of March 31, 2025, the company held $103.3 million in cash, cash equivalents, and marketable securities.
• Management believes current resources will fund operations into the fourth quarter of 2026.
• The company expects to incur substantial additional expenditures for ongoing and planned clinical trials and will require substantial additional funding to complete development and commercialization.

• Capital Needs: Failure to raise additional capital could force delays or abandonment of development programs.
• Clinical Uncertainty: Outcomes of current trials may not predict future success; patient enrollment delays remain a risk.
• Regulatory Pathway: The company intends to pursue FDA approval via the Section 505(b)(2) pathway, which carries uncertainty regarding the requirement for additional clinical data.
• Single Product Dependence: The business relies entirely on the success of Haduvio.

Investor Verification Checklist

• Verify the timing and results of the Phase 2b CORAL topline data announcement expected in Q2 2025.
• Monitor the design and initiation timeline of the next RCC clinical trial following the positive RIVER data.
• Assess the company's cash burn rate relative to the projected runway into Q4 2026 and potential dilution from future equity financings.
• Review the status of the Section 505(b)(2) regulatory strategy and any feedback received from the FDA regarding the Phase 3 program design.
• Track the exercise of remaining pre-funded warrants and their potential impact on share count and dilution.